We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Q3 Loss Wider Than Expected, Revenues Top
Read MoreHide Full Article
Teladoc Inc.’s (TDOC - Free Report) third-quarter 2017 operating loss of 55 cents per share was wider than the Zacks Consensus Estimate of a loss of 50 cents. In the year-ago quarter, the company had incurred a loss of 33 cents per share.
Operational Update
Total revenues of $69 million not only surpassed the Zacks Consensus Estimate of $68 million but also surged 112% year over year. This is above the company’s guided range of $67-$68 million.
Revenues from subscription access fees and visit fees were $59.8 million and $8.9 million, respectively, reflecting an increase of 115% and 94% year over year. The rise in subscription fees indicates overall membership expansion and total visit growth.
Total visits of 306,000 surged 51% year over year and total U.S.paid membership was 22.6 million, reflecting an increase of 33%. Both of these surpassed the company’s guided range of 275,000-300,000 and 22.0-22.5 million, respectively.
Total operating expenses were $73.4 million, 61% higher year over year. The rise was due to increased expenditure on advertising & marketing, sales, technology & development, acquisition related costs, general & administrative expenses as well as depreciation & amortization costs.
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) narrowed to a loss of $0.6 million from a loss of $9.3 million in the year-ago quarter and came in better than the company’s guided range of a loss of $2-$3 million.
Teladoc’s total assets were approximately $880 million as of Sep 30, 2017, up from $303.7 million as of Dec 31, 2016.
Total cash, cash equivalents and marketable securities were $83.1 million as of Sep 30, 2017, up from $50 million as of Dec 31, 2016.
Fourth-Quarter Guidance
Net loss per share, based on 57.1 million weighted average shares outstanding, is expected to be between 41 cents and 43 cents.
Revenues are expected to be in the range of $75-$77 million.
Adjusted EBITDA is expected to be in the range of $1-$2 million.
Membership is expected to be between 22.6 million and 23 million.
Total visits are projected within the range of 4,00,00–4,50,000.
2017 Guidance
Net loss per share, based on 55.1 million weighted average shares outstanding, is expected to be between $1.56 and $1.58, wider than the previously guided range of a loss of $1.52 to $1.55.
Revenues are expected to be in the range of $231 million to $233 million compared with the previously guided range of $230-$235 million.
Adjusted EBITDA is expected to be in the range of a loss of $14-$15 million compared with the previously guided range of a loss of $15-$17 million
Membership is expected to lie within 22.6 million to 23 million compared with the previously guided band of 22.5-23.0 million.
Total visits are projected to be between 1,400,000 and 1,450,000, unchanged from the previous guidance.
Among the other firms in the medical sector that have reported third-quarter earnings so far, the bottom lines of Anthem Inc., Aetna Inc. and UnitedHealth Group Inc. (UNH - Free Report) beat their respective Zacks Consensus Estimate.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Image: Bigstock
Teladoc (TDOC) Q3 Loss Wider Than Expected, Revenues Top
Teladoc Inc.’s (TDOC - Free Report) third-quarter 2017 operating loss of 55 cents per share was wider than the Zacks Consensus Estimate of a loss of 50 cents. In the year-ago quarter, the company had incurred a loss of 33 cents per share.
Operational Update
Total revenues of $69 million not only surpassed the Zacks Consensus Estimate of $68 million but also surged 112% year over year. This is above the company’s guided range of $67-$68 million.
Revenues from subscription access fees and visit fees were $59.8 million and $8.9 million, respectively, reflecting an increase of 115% and 94% year over year. The rise in subscription fees indicates overall membership expansion and total visit growth.
Total visits of 306,000 surged 51% year over year and total U.S.paid membership was 22.6 million, reflecting an increase of 33%. Both of these surpassed the company’s guided range of 275,000-300,000 and 22.0-22.5 million, respectively.
Total operating expenses were $73.4 million, 61% higher year over year. The rise was due to increased expenditure on advertising & marketing, sales, technology & development, acquisition related costs, general & administrative expenses as well as depreciation & amortization costs.
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) narrowed to a loss of $0.6 million from a loss of $9.3 million in the year-ago quarter and came in better than the company’s guided range of a loss of $2-$3 million.
Teladoc, Inc. Price, Consensus and EPS Surprise
Teladoc, Inc. Price, Consensus and EPS Surprise | Teladoc, Inc. Quote
Financial Position
Teladoc’s total assets were approximately $880 million as of Sep 30, 2017, up from $303.7 million as of Dec 31, 2016.
Total cash, cash equivalents and marketable securities were $83.1 million as of Sep 30, 2017, up from $50 million as of Dec 31, 2016.
Fourth-Quarter Guidance
Net loss per share, based on 57.1 million weighted average shares outstanding, is expected to be between 41 cents and 43 cents.
Revenues are expected to be in the range of $75-$77 million.
Adjusted EBITDA is expected to be in the range of $1-$2 million.
Membership is expected to be between 22.6 million and 23 million.
Total visits are projected within the range of 4,00,00–4,50,000.
2017 Guidance
Net loss per share, based on 55.1 million weighted average shares outstanding, is expected to be between $1.56 and $1.58, wider than the previously guided range of a loss of $1.52 to $1.55.
Revenues are expected to be in the range of $231 million to $233 million compared with the previously guided range of $230-$235 million.
Adjusted EBITDA is expected to be in the range of a loss of $14-$15 million compared with the previously guided range of a loss of $15-$17 million
Membership is expected to lie within 22.6 million to 23 million compared with the previously guided band of 22.5-23.0 million.
Total visits are projected to be between 1,400,000 and 1,450,000, unchanged from the previous guidance.
Zacks Rank & Performance of Other Insurers
Teladoc currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Among the other firms in the medical sector that have reported third-quarter earnings so far, the bottom lines of Anthem Inc., Aetna Inc. and UnitedHealth Group Inc. (UNH - Free Report) beat their respective Zacks Consensus Estimate.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>